MarginsXMarginsX
Home › Markets › Health Care › INCY

Incyte Corp. (INCY)

INCY trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$120.27
-0.58% on the day
Market cap
$24.5B
Large cap
Revenue · 2025
$5.1B
+21.2% on 2024
Net income · 2025
$1.3B
25.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/0000879169-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerINCY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000879169
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDE

Financials · 2025

LineValue
Revenue$5.1B
Net income$1.3B
Operating income$1.5B
Net margin25.0%
Operating margin29.5%
Revenue growth+21.2%
Cash$3.1B
Total assets$7.0B
P/E (computed)19.1×
P/S (computed)4.8×

Warning signs

Cash runway
Cash-flow positive
$3.3B cash at September 30, 2026
Share count, 1 year
+3.8%
2025-10-21 to 2026-10-22 · -9.0% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$58.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$3.3B cash; operating cash flow $186.2M a quarter.Report 2026-09-30
Shares outstanding203,832,492 (2026-10-22); 196,322,703 a year earlier; 224,109,238 three years earlier.Cover page 2026-10-22
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-02-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $58.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.6B-$784.8M-$675.3M$3.3BNo debt tags$6.0B10-Q 2026-10-29
Q2 2026
2026-06-30
$1.7B$585.6M$507.7M$4.0BNo debt tags$5.8B10-Q 2026-07-28
Q1 2026
2026-03-31
$1.3B$303.3M$369.4M$3.5BNo debt tags$5.4B10-Q 2026-04-28
Q4 2025
2025-12-31
$1.5B$299.3M$543.3M$3.1BNo debt tags$5.1B10-K 2026-02-10
Q3 2025
2025-09-30
$1.4B$424.2M$559.4M$2.5BNo debt tags$4.8B10-Q 2026-10-29
Q2 2025
2025-06-30
$1.2B$405.0M$44.7M$2.0BNo debt tags$4.6B10-Q 2026-07-28
Q1 2025
2025-03-31
$1.1B$158.2M$266.1M$1.9BNo debt tags$4.4B10-Q 2026-04-28
Q4 2024
2024-12-31
$1.2B$201.2M$381.2M$1.7BNo debt tags$4.2B10-K 2026-02-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-02-10
Latest annual report10-K2026-02-10
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-05-27

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.1%
1 month+11.4%
3 months+0.4%
Year to date+22.5%
1 year+14.8%
From 52-week high-6.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
MEDPMedpace Holdings Inc.$648.20-0.88%$18.1B
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B
ICLRICON plc$191.40-1.67%$14.7B
IQVIQVIA Holdings Inc.$264.73-0.15%$43.6B
ABSIAbsci Corporation$7.47-11.54%$1.3B
OABIOmniAb Inc.$4.89-0.41%$713.3M
NRCNRC Health$26.33-0.87%$558.8M
MXCTMaxCyte Inc.$1.18-0.84%$121.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier